Mangoceuticals, INC. (MGRX) — SEC Filings

Overview

Mangoceuticals, INC. (MGRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Apr 1, 2026: MANGOCEUTICALS, INC. (MGRX) focuses on men's wellness products and telemedicine services, including treatments for erectile dysfunction (Mango ED), hair loss (Grow), hormone balance (Mojo), and weight management (Slim). All Compounded Products are produced and fulfilled by Epiq Scripts, LLC, a relat

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Mangoceuticals, INC. is neutral.

Filing Type Overview

Mangoceuticals, INC. (MGRX) has filed 2 10-K, 42 8-K, 1 10-Q/A, 3 10-Q, 1 DEF 14A, 1 SC 13D/A with the SEC between Aug 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• MGRX Under Scrutiny After Reverse Split, Trading Irregularities — 10-K · Apr 1, 2026 Risk: high
  MANGOCEUTICALS, INC. (MGRX) focuses on men's wellness products and telemedicine services, including treatments for erectile dysfunction (Mango ED), hair loss (G
• MANGOCEUTICALS, INC. Files 8-K for Material Agreement — 8-K · Dec 19, 2025 Risk: medium
  On December 17, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company, incorporated in Texas with EIN 873841292, filed a Form 8-K
• MANGOCEUTICALS, INC. Enters Material Definitive Agreement — 8-K · Dec 10, 2025 Risk: medium
  On December 4, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. This agreement also created a direct financial obligation or an obligati
• MGRX Net Loss Doubles Amid Soaring Operating Costs, Revenue Declines — 10-Q/A · Nov 14, 2025 Risk: high
  MANGOCEUTICALS, INC. (MGRX) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $(10,255,309) compared to $(4,758,936)
• 8-K Filing — 8-K · Nov 13, 2025
• MANGOCEUTICALS, INC. Files 8-K with Multiple Agreements and Equity Changes — 8-K · Oct 29, 2025 Risk: medium
  On September 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement and also terminated a material definitive agreement. The company also c
• MANGOCEUTICALS, INC. Files 8-K on Director Changes and Compensation — 8-K · Sep 12, 2025 Risk: low
  On September 9, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing a
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · Sep 2, 2025 Risk: medium
  On August 26, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• Mangoceuticals Files 10-Q for Q2 2025 — 10-Q · Aug 14, 2025 Risk: medium
  Mangoceuticals, Inc. filed its 10-Q for the period ending June 30, 2025, reporting on its financial performance. The filing details various financial instrument
• MANGOCEUTICALS, INC. Files 8-K with Key Agreements and Asset Changes — 8-K · Aug 4, 2025 Risk: medium
  On July 30, 2025, MANGOCEUTICALS, INC. reported the entry into a material definitive agreement, the termination of a material definitive agreement, and the comp
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales — 8-K · Jul 23, 2025 Risk: medium
  On June 10, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and fi
• MANGOCEUTICALS, INC. Files 8-K with Bylaw Amendments and Exhibits — 8-K · Jul 10, 2025 Risk: low
  On July 3, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing amendments to its articles of incorporation or bylaws and including financial statements and
• MANGOCEUTICALS, INC. Reports Director and Officer Changes — 8-K · Jul 3, 2025 Risk: medium
  On July 1, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information on
• MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — 8-K · Jun 10, 2025 Risk: medium
  On June 2, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number of
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales — 8-K · May 30, 2025 Risk: medium
  On May 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and fil
• Mangoceuticals Reports Material Agreements and Asset Changes — 8-K · May 23, 2025 Risk: medium
  On May 22, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing several material events. These include the entry into and termination of a material definiti
• Mangoceuticals, Inc. Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Mangoceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · May 6, 2025 Risk: medium
  On April 28, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unreg
• MANGOCEUTICALS, INC. Completes Acquisition, Announces Officer Changes — 8-K · Apr 25, 2025 Risk: medium
  On April 24, 2025, MANGOCEUTICALS, INC. reported the completion of an acquisition. The company also announced the departure of a director and the appointment of
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Debt, Equity Sales — 8-K · Apr 17, 2025 Risk: medium
  On April 11, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation an
• MANGOCEUTICALS, INC. Reports Board & Executive Changes — 8-K · Apr 11, 2025 Risk: medium
  On April 10, 2025, MANGOCEUTICALS, INC. reported changes in its board of directors and executive compensation. The filing details the departure of certain offic
• MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — 8-K · Apr 8, 2025 Risk: medium
  On March 28, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number o
• MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — 8-K · Apr 2, 2025 Risk: medium
  On March 28, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose specific details regarding the number o
• MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — 8-K · Mar 28, 2025 Risk: medium
  On March 25, 2025, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The company, incorporated in Texas with its principal executive offi
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 25, 2025 Risk: medium
  On March 20, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and pro
• Mangoceuticals Files 2024 Annual Report — 10-K · Mar 20, 2025 Risk: medium
  Mangoceuticals, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Texas, operates
• MANGOCEUTICALS, INC. Files 8-K with Equity, Governance Updates — 8-K · Mar 19, 2025 Risk: medium
  On March 17, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing several key events. These include unregistered sales of equity securities, material modifi
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 19, 2025 Risk: medium
  On February 14, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
• Mangoceuticals Files Definitive Proxy Statement — DEF 14A · Feb 18, 2025 Risk: low
  Mangoceuticals, Inc. filed its definitive proxy statement on February 18, 2025, for its annual meeting. The company, located at 15110 Dallas Pkwy, Suite 600, Da
• MANGOCEUTICALS, INC. Files 8-K Report — 8-K · Feb 12, 2025 Risk: low
  On February 12, 2025, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specifi
• MANGOCEUTICALS, INC. Files 8-K: Equity Sales, Officer Changes, Financials — 8-K · Feb 7, 2025 Risk: medium
  On February 3, 2025, MANGOCEUTICALS, INC. reported on several key events. The company disclosed unregistered sales of equity securities and announced changes in
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 31, 2025 Risk: medium
  On January 27, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity sec
• MANGOCEUTICALS, INC. Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Jan 21, 2025 Risk: medium
  On January 15, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• MANGOCEUTICALS, INC. Files 8-K: Rights, Bylaws, and Financials Updated — 8-K · Jan 15, 2025 Risk: low
  On January 9, 2025, MANGOCEUTICALS, INC. filed an 8-K report detailing material modifications to the rights of its security holders. The filing also includes am
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 8, 2025 Risk: medium
  On December 31, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement, unregistered sales of equity securities, and financial
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 26, 2024 Risk: medium
  On December 18, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
• MANGOCEUTICALS, INC. Completes Asset Acquisition, Discloses Equity Sales — 8-K · Dec 19, 2024 Risk: medium
  On December 13, 2024, MANGOCEUTICALS, INC. announced the completion of its acquisition of certain assets. The filing also disclosed unregistered sales of equity
• MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 6, 2024 Risk: medium
  On December 2, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity sec
• Mangoceuticals Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Mangoceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial information and operational updates for the third qua
• Mangoceuticals Adds Director, Discloses Officer Compensation — 8-K · Nov 12, 2024 Risk: low
  Mangoceuticals, Inc. announced on November 11, 2024, the election of Dr. David G. Smith as a new Class III Director, effective immediately. Dr. Smith brings ext
• MANGOCEUTICALS, INC. Files 8-K Report — 8-K · Oct 31, 2024 Risk: low
  On October 30, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements and exhibits. The company is
• MANGOCEUTICALS, INC. Reports Unregistered Equity Sale — 8-K · Oct 25, 2024 Risk: medium
  On October 18, 2024, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The company, incorporated in Texas with its principal executive of
• MANGOCEUTICALS, INC. Enters Material Definitive Agreement — 8-K · Oct 22, 2024 Risk: medium
  On October 18, 2024, MANGOCEUTICALS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Tex
• MANGOCEUTICALS, INC. Files 8-K Report — 8-K · Oct 21, 2024 Risk: low
  On October 21, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements
• MANGOCEUTICALS, INC. Files 8-K on Security Holder Rights — 8-K · Oct 11, 2024 Risk: low
  On October 8, 2024, MANGOCEUTICALS, INC. filed an 8-K report detailing material modifications to security holder rights and other events. The company, incorpora
• MANGOCEUTICALS, INC. Files 8-K Report — 8-K · Oct 3, 2024 Risk: low
  On October 3, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
• MANGOCEUTICALS, INC. Reports Unregistered Equity Sales — 8-K · Oct 2, 2024 Risk: medium
  On August 15, 2024, MANGOCEUTICALS, INC. reported unregistered sales of equity securities. The filing does not disclose specific details regarding the number of
• MANGOCEUTICALS, INC. Files 8-K Report — 8-K · Oct 1, 2024 Risk: low
  On October 1, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific mat
• Mangoceuticals Reports Unregistered Equity Sale — 8-K · Sep 27, 2024 Risk: medium
  On September 26, 2024, MANGOCEUTICALS, INC. reported an unregistered sale of equity securities. The filing does not disclose the specific details of the sale, s
• Cohen Amends MANGOCEUTICALS Stake Filing — SC 13D/A · Aug 27, 2024 Risk: medium
  Jacob D. Cohen filed an amendment (No. 3) to Schedule 13D on August 27, 2024, regarding his holdings in MANGOCEUTICALS, INC. The filing indicates a change in th

Risk Profile

Risk Assessment: Of MGRX's 49 recent filings, 2 were flagged as high-risk, 36 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Mangoceuticals, INC.'s most recent 10-K filing (Apr 1, 2026):

• Revenue: $14.7M
• Net Income: N/A
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Jacob Cohen
• Chief Executive Officer
• Dr. David G. Smith
• Jacob D. Cohen

Industry Context

MANGOCEUTICALS operates in the growing men's wellness sector, which leverages telemedicine for discreet access to treatments for conditions like erectile dysfunction, hair loss, and hormone imbalances. The industry is characterized by increasing consumer demand for personalized health solutions and a shift towards digital health platforms. However, it faces intense competition from both specialized online providers and traditional healthcare services.

Top Tags

equity-sale (20) · material-agreement (17) · financials (10) · filing (6) · 8-k (6) · unregistered-sale (5) · equity-securities (5) · financial-obligation (4) · corporate-governance (3) · executive-compensation (3)

Executive Compensation

From the most recent 10-K filing (Apr 1, 2026):

• Jacob Cohen — Chief Executive Officer: $1,200,000

Key Numbers

• Aggregate market value of non-affiliate common stock: $14.7M — As of June 30, 2025, based on a $1.52 closing price.
• Reverse Stock Split Ratio: 1-for-15 — Effective October 16, 2024, reducing outstanding shares from 35.5 million to 2.4 million.
• Ownership of Epiq Scripts, LLC: 52% — Owned by CEO Jacob Cohen, highlighting related-party dependency.
• Post-split outstanding common shares: 2.4M — Reduced from approximately 35.5 million after the October 16, 2024 reverse stock split.
• Public Reporting Company Date: March 20, 2023 — Date MGRX became a public reporting company via its S-1 effectiveness.
• Net loss for six months ended June 30, 2025: $(10,255,309) — Increased 115.49% from $(4,758,936) in prior year
• Revenues for six months ended June 30, 2025: $277,415 — Decreased 26.47% from $377,258 in prior year
• Total operating expenses for six months ended June 30, 2025: $10,273,696 — Increased from $4,753,448 in prior year
• Stock-based compensation for six months ended June 30, 2025: $4,165,924 — Increased 217.10% from $1,313,845 in prior year
• Investor relations expenses for six months ended June 30, 2025: $1,525,000 — Increased from $183,000 in prior year
• Cash and cash equivalents as of June 30, 2025: $101,019 — Increased from $58,653 at December 31, 2024
• Total current liabilities as of June 30, 2025: $1,600,945 — Increased from $1,425,463 at December 31, 2024
• Intangible assets (acquired patents and license) as of June 30, 2025: $20,694,893 — Increased from $15,232,617 at December 31, 2024
• Reverse Stock Split ratio: 1-for-15 — Effective October 16, 2024
• Shares of common stock outstanding as of August 14, 2025: 10,535,791 — Post-Reverse Stock Split

Related Companies

HIMS · MOGO

Frequently Asked Questions